Cargando…

Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up

Prostate cancer (PCa) is the most prevalent among men, and psychological symptoms may affect many patients. This study aims to describe the prevalence of probable anxiety and depression before PCa treatments and after one year and to identify sociodemographic and clinical factors associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte, Vítor, Araújo, Natália, Lopes, Catarina, Costa, Adriana, Ferreira, Augusto, Carneiro, Filipa, Oliveira, Jorge, Braga, Isaac, Morais, Samantha, Pacheco-Figueiredo, Luís, Ruano, Luis, Tedim Cruz, Vítor, Pereira, Susana, Lunet, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368515/
https://www.ncbi.nlm.nih.gov/pubmed/35897487
http://dx.doi.org/10.3390/ijerph19159122
_version_ 1784766158962950144
author Duarte, Vítor
Araújo, Natália
Lopes, Catarina
Costa, Adriana
Ferreira, Augusto
Carneiro, Filipa
Oliveira, Jorge
Braga, Isaac
Morais, Samantha
Pacheco-Figueiredo, Luís
Ruano, Luis
Tedim Cruz, Vítor
Pereira, Susana
Lunet, Nuno
author_facet Duarte, Vítor
Araújo, Natália
Lopes, Catarina
Costa, Adriana
Ferreira, Augusto
Carneiro, Filipa
Oliveira, Jorge
Braga, Isaac
Morais, Samantha
Pacheco-Figueiredo, Luís
Ruano, Luis
Tedim Cruz, Vítor
Pereira, Susana
Lunet, Nuno
author_sort Duarte, Vítor
collection PubMed
description Prostate cancer (PCa) is the most prevalent among men, and psychological symptoms may affect many patients. This study aims to describe the prevalence of probable anxiety and depression before PCa treatments and after one year and to identify sociodemographic and clinical factors associated with these outcomes. Between February 2018 and March 2020, 292 patients recently diagnosed with PCa were recruited at the Instituto Português de Oncologia—Porto. The Hospital Anxiety and Depression Scale (HADS) was used to define probable anxiety and depression (cutoff = 11). The prevalence of probable anxiety remained stable from baseline to one year (7.8% vs. 8.5%, p = 0.866) while there was an increase in probable depression (3.1% vs. 6.8%, p = 0.012). After one year, probable depression persisted in 55.6% of patients with probable depression at baseline and 47.8% of those with probable anxiety at the first assessment had normal anxiety scores. At baseline, anxiety was more frequent among dwellers in rural areas (adjusted odds ratio—aOR, 95%CI: 2.80, 0.91–8.58) and less frequent in patients with body mass index 25–29.9 kg/m(2) (aOR, 95%CI: 0.33, 0.12–0.91) compared to 18.5–24.9 Kg/m(2), while those living alone had higher odds of depression (aOR, 95%CI: 6.35, 1.43–28.30). The frequency of anxiety and depression fluctuated during the course of treatment. Monitoring these symptoms would identify the most affected patients, contributing for a better use of mental health services.
format Online
Article
Text
id pubmed-9368515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93685152022-08-12 Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up Duarte, Vítor Araújo, Natália Lopes, Catarina Costa, Adriana Ferreira, Augusto Carneiro, Filipa Oliveira, Jorge Braga, Isaac Morais, Samantha Pacheco-Figueiredo, Luís Ruano, Luis Tedim Cruz, Vítor Pereira, Susana Lunet, Nuno Int J Environ Res Public Health Article Prostate cancer (PCa) is the most prevalent among men, and psychological symptoms may affect many patients. This study aims to describe the prevalence of probable anxiety and depression before PCa treatments and after one year and to identify sociodemographic and clinical factors associated with these outcomes. Between February 2018 and March 2020, 292 patients recently diagnosed with PCa were recruited at the Instituto Português de Oncologia—Porto. The Hospital Anxiety and Depression Scale (HADS) was used to define probable anxiety and depression (cutoff = 11). The prevalence of probable anxiety remained stable from baseline to one year (7.8% vs. 8.5%, p = 0.866) while there was an increase in probable depression (3.1% vs. 6.8%, p = 0.012). After one year, probable depression persisted in 55.6% of patients with probable depression at baseline and 47.8% of those with probable anxiety at the first assessment had normal anxiety scores. At baseline, anxiety was more frequent among dwellers in rural areas (adjusted odds ratio—aOR, 95%CI: 2.80, 0.91–8.58) and less frequent in patients with body mass index 25–29.9 kg/m(2) (aOR, 95%CI: 0.33, 0.12–0.91) compared to 18.5–24.9 Kg/m(2), while those living alone had higher odds of depression (aOR, 95%CI: 6.35, 1.43–28.30). The frequency of anxiety and depression fluctuated during the course of treatment. Monitoring these symptoms would identify the most affected patients, contributing for a better use of mental health services. MDPI 2022-07-26 /pmc/articles/PMC9368515/ /pubmed/35897487 http://dx.doi.org/10.3390/ijerph19159122 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Duarte, Vítor
Araújo, Natália
Lopes, Catarina
Costa, Adriana
Ferreira, Augusto
Carneiro, Filipa
Oliveira, Jorge
Braga, Isaac
Morais, Samantha
Pacheco-Figueiredo, Luís
Ruano, Luis
Tedim Cruz, Vítor
Pereira, Susana
Lunet, Nuno
Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title_full Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title_fullStr Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title_full_unstemmed Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title_short Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up
title_sort anxiety and depression in patients with prostate cancer, at cancer diagnosis and after a one-year follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368515/
https://www.ncbi.nlm.nih.gov/pubmed/35897487
http://dx.doi.org/10.3390/ijerph19159122
work_keys_str_mv AT duartevitor anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT araujonatalia anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT lopescatarina anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT costaadriana anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT ferreiraaugusto anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT carneirofilipa anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT oliveirajorge anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT bragaisaac anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT moraissamantha anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT pachecofigueiredoluis anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT ruanoluis anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT tedimcruzvitor anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT pereirasusana anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup
AT lunetnuno anxietyanddepressioninpatientswithprostatecanceratcancerdiagnosisandafteraoneyearfollowup